• location:

single center in Wuhan, China

• participation eligibility:

age: 18 years or older, HIV-negative, previous SARS-CoV-2 infection-free, axillary temp: 37.0 deg C or less, BMI: 18.5-30.0, general good health, no pregnant/breastfeeding women, no people with mental disease, allergies, cardiovascular disease, other chronic illnesses

• randomized, double-blinded, placebo-controlled

1 x 10^11, 5x10^10 viral particles per mL, placebo were randomized at 2:1:1 ratio

• procedure:

single injection, IM, arm, participants monitored (blood samples collected for antibody responses) for 30 mins, follow-up within 14 days, 28 days, and 6 months, self-reported serious effects, detection limit for RBD = 1:40, for neutralizing antibody to live SARS-CoV-2 virus and a pesudovirus = 1:8 and 1:10, respectively, expression of IFN detected by enzyme-linked immunospot (ELISpot) assay

(see children nodes for more information)